Kinetics of human acetylcholinesterase inhibition by the novel experimental alzheimer therapeutic agent, tolserine

Biochemical Pharmacology

Volumn 60, Issue 4, 2000, Pages 561-570

  Kamal, Mohammad A ^a   Greig, Nigel H ^b   Alhomida, Abdullah S ^a   Al Jafari, Abdulaziz A ^c  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c NONE

Author keywords

Acetylcholinesterase; Alzheimer's disease; Inhibition; Kinetics; Novel; Tolserine

Indexed keywords

ACETYLCHOLINESTERASE; ACETYLTHIOCHOLINE; CHOLINESTERASE INHIBITOR; ESEROLINE; PHENSERINE; PHYSOSTIGMINE; TOLSERINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CHEMICAL REACTION KINETICS; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME KINETICS; ERYTHROCYTE; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; REGRESSION ANALYSIS;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; BINDING, COMPETITIVE; CHOLINESTERASE INHIBITORS; HUMANS; KINETICS; PHYSOSTIGMINE;

EID: 0034664203     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00330-0     Document Type: Article

References (48)

1. Giacobini E. Cholinesterase inhibitors do more than inhibit cholinesterase. Becker R., Giacobini E. Alzheimer's Disease from Molecular Biology to Therapy . 1997;187-204 Birkhauser, Boston.
2. Kasa P., Rakonczay Z., Gulya K. The cholinergic system in Alzheimer's disease. Prog Neurobiol. 52:1997;511-532.
3. Deutsch J. The cholinergic synapse and the site of memory. Science. 313:1985;7-11.
4. Avery E.E., Baker L.D., Asthana S. Potential role of muscarinic agonists in Alzheimer's disease. Drugs Aging. 11:1997;450-459.
5. Newhouse P.A., Potter A., Levin E.D. Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics. Drugs Aging. 11:1997;206-208.
6. Soreq H and Zakut H, Molecular polymorphism and its genomic origin. In: Human Cholinesterases and Anti-cholinesterases, pp. 41-45. Academic Press, New York, 1993.
7. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., Katzman R. Physical basis of cognitive alterations in Alzheimer's disease Synapse loss is the major correlate of cognitive impairment . Ann Neurol. 30:1991;572-580.
8. Gracon S., Smith F., Hoover T., Knopman D., Schneider L., Davis K., Talwalker S. Long-term tacrine treatment Effect on nursing home placement and mortality . Becker R., Giacobini E. Alzheimer's Disease from Molecular Biology to Therapy . 1997;205-209 Birkhauser, Boston.
9. Blackard W.G. Jr, Sood G.K., Crowe D.R., Fallon M.B. Tacrine. A cause of fatal hepatotoxicity? J Clin Gastroenterol. 26:1998;57-59.
10. Barner E.L., Gray S.L. Donepezil use in Alzheimer disease. Ann Pharmacother. 32:1998;70-77.
11. Becker R., Moriearty P., Unni L. The second generation of cholinesterase inhibitors Clinical and pharmacological effects . Becker R., Giacobini E. Cholinergic Basis of Alzheimer's Disease. 1991;263-296 Birkhauser, Boston.
12. Yu Q.S., Holloway H.W., Utsuki T., Brossi A., Greig N.H. Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's Disease. J Med Chem. 42:1999;1855-1861.
13. Lahiri D.K., Farlow M.R., Sambamurti K. The secretion of amyloid β-peptides in inhibited in tacrine-treated human neuroblastoma cells. Mol Brain Res. 62:1998;131-140.
14. Lahiri D.K., Farlow M.R., Nurnberger J.I. Jr, Greig N.H. Effects of cholinesterase inhibitors on the secretion of beta-amyloid precursor protein in cell cultures. Ann N Y Acad Sci. 826:1997;416-421.
15. Al-Jafari A.A., Kamal M.A., Greig N.H., Alhomida A.S., Perry E.R. Kinetics of human erythrocyte acetylcholinesterase inhibition by a novel derivative of physostigmine Phenserine . Biochem Biophys Res Commun. 248:1998;180-185.
16. Liston D., Nielsen J.A., Villalobos A., Chapin D., Jones S.B., Hubbard S., Shalaby I., White W.F. CP-118,954 A potent and selective AChE inhibitor. The importance of selective AChE inhibition in vivo . Proc Soc Neurosci. 20:1994;608-611.
17. Iijima S., Greig N.M., Garofolo P., Spangler E.L., Heller B., Brossi A., Ingram D.K. Phenserine A physostigmine derivative that is a long-acting inhibitor of cholinesterase and demonstrates a wide dose range for attenuating a scopolamine-induced learning impairment of rats in a 14-unit T-maze . Psychopharmacology (Berl). 112:1993;415-420.
18. Patel N., Spangler E.L., Greig N.H., Yu Q.S., Ingram D.K., Meyer R.C. Tolserine, a novel acetylcholinesterase inhibitor, attenuates impaired learning of rats in a 14-unit T-maze induced by blockade of the N-methyl-D-aspartate receptor. Neuroreport. 9:1998;171-176.
19. Selkoe D.J. Alzheimer's disease A central role of β-amyloid . J Neuropathol Exp Neurol. 53:1994;438-447.
20. Haroutunian V., Greig N.H., Utsuki T., Davis K.L., Wallace W.C. Pharmacological modulation of Alzheimer's β-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions. Mol Brain Res. 46:1997;161-168.
21. Meyer RC, Munoz JR, Patel N, Knox J, Sohn J, Utsuki T, Holloway HW, Greig NH and Ingram DK, Complex maze learning is improved in aged rats treated with novel and long-acting acetylcholinesterase inhibitors. Neuropharmacoly, in press.
22. Greig N.H., Pei X.-F., Soncrant T.T., Ingram D.K., Brossi A. Phenserine and ring C hetero-analogues Drug candidates for the treatment of Alzheimer's disease . Med Res Rev. 15:1995;3-31.
23. Ellman G.L., Courtney D., Andres V. Jr, Featherstone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 7:1961;88-95.
24. Al-Jafari A.A., Kamal M.A. Optimization and kinetic studies of human erythrocyte membrane-bound acetylcholinesterase. Biochem Mol Biol Int. 38:1996;577-586.
25. Erithacus Software, Hill plot. In: GraFit User's Guide (Ed. Leatherbarrow RJ), Version 3.0, p. 267. Erithacus Software Ltd., Staines, U.K., 1992.
26. Al-Jafari A.A., Kamal M.A., Duhaiman A.S., Alhomida A.S. Kinetics of the inhibition of acetylcholinesterase from desert cobra (Walterinnesia aegyptia) venom by local anesthetics Procaine and tetracaine . J Enz Inhib. 11:1996;123-134.
27. Kamal M.A., Nasim F.H., Al-Jafari A.A. Investigation of the effect of anti-neoplastic drugs, cyclophosphamide, cisplatin and methotrexate on the turnover kinetics of human erythrocyte acetylcholinesterase. Biochem Mol Biol Int. 39:1996;293-302.
28. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin Phenol reagent. J Biol Chem. 193:1951;265-275.
29. Leatherbarrow R.J. GraFit. Version 3.0. Erithacus Software Ltd. 1992;Staines, UK.
30. Giacobini E. From molecular structure to Alzheimer therapy. Jpn J Pharmacol. 74:1997;225-241.
31. Harris L.W., Anderson D.R., Pastelak A.M., Bowersox S.L., Vanderpool B.A., Lennox W.J. Acetylcholinesterase inhibition and anti-soman efficacy of homologs of physostigmine. Drug Chem Toxicol. 15:1992;127-143.
32. Thomsen T., Kaden B., Fischer J.P., Bickel U., Barz H., Gusztony G., Cervos-Navarro J., Kewitz H. Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine and tacrine. Eur J Clin Chem Clin Biochem. 29:1991;487-492.
33. Duhaiman A., Alhomida A.S., Rabbani N., Kamal M.A., Al-Jafari A.A. Purification and characterization of acetylcholinesterase from desert cobra (Walterinessia aegyptia) venom. Biochimie. 77:1996;46-50.
34. Chan S.L., Shirachi D.Y., Bhargava H.N., Gardner E., Trevor A.J. Purification and properties of multiple forms of brain acetylcholinesterase (EC 3.1.1.7). J Neurochem. 19:1972;2747-2758.
35. Al-Jafari A.A. The nature of the inhibition of camel retina acetylcholinesterase (EC 3.1.1.7) activity by tetrahydroaminoacridine. J Ocul Pharmacol Ther. 12:1996;503-513.
36. Gupta S., Sanyal S.N., Duggal C.L. Study of the acetylcholinesterase activity of Ascaridia galli Kinetic properties and the effect of anthelmintics . Acta Vet Hung. 39:1991;165-174.
37. Cohen S.G., Chishti S.B., Bell D.A., Howard S.I., Salih E., Cohen J.B. General occurrence of binding to acetylcholinesterase-substrate complex in noncompetitive inhibition and in inhibition by substrate. Biochim Biophys Acta. 1076:1991;112-122.
38. Kamal M.A. Investigation of the effect of lannate on kinetic parameters of acetylcholinesterase Slightly concave mixed-type of inhibition system . Biochem Mol Biol Int. 43:1997;1183-1193.
39. Perola E., Cellai L., Lamba D., Filocamo L., Brufani M. Long chain analogs of physostigmine as potential drugs for Alzheimer's disease New insights into the mechanism of action in the inhibition of acetylcholinesterase . Biochim Biophys Acta. 1343:1997;41-50.
40. Atack J.R., Yu Q.S., Soncrant T.T., Brossi A., Rapoport S.I. Comparative inhibitory effects of various physostigmine analogues against acetyl- and butyrylcholinesterase. J Pharmacol Exp Ther. 249:1989;194-202.
41. Perry E.K., Perry R.H., Blessed G., Tomlinson B.E. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol. 4:1978;273-277.
42. Ott P., Lustig A., Brodbeck U., Rosenbusch J.P. Acetylcholinesterase from human erythrocyte membrane Dimers as functional units . FEBS Lett. 138:1982;187-189.
43. Massoulie J., Anselmet A., Bon S., Krejci E., Legay C., Morel N., Simon S. Acetylcholinesterase C-terminal domains, molecular forms and functional localization . J Physiol (Paris). 92:1998;183-190.
44. Yu QS, Holloway HW, Brossi A and Greig NH, Substituted phenserine: Syntheses and anti-cholinesterase structure/activities relationships. J Med Chem, in press.
45. Greig NH, Drug entry to the brain and its pharmacologic manipulation. In: Handbook of Experimental Pharmacology (Ed. Bradbury MW), Vol 103, pp. 487-523. Springer-Verlag, Heidelberg, Germany, 1992.
46. Stein H.H., Lewis G.J. Noncompetitive inhibition of acetylcholinesterase by eserine. Biochem Pharmacol. 18:1969;1679-1684.
47. Galli A., Renzi G., Grazzini E., Bartolini R., Aiello-Malmberg P., Bartolini A. Reversible inhibition of acetylcholinesterase by eseroline, an opioid agonist structurally related to physostigmine (eserine) and morphine. Biochem Pharmacol. 31:1982;1233-1238.
48. Segel I.H. Rapid equilibrium partial and mixed-type inhibition. Enzyme Kinetics Behavior and Analysis of Rapid Equilibrium and Steady State Enzyme Systems . 1975;166-169 J Wiley, New York.